NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New eye implant could cut injections from monthly to twice a year for wet AMD patients
Disease control Recruiting nowThis study tests a small implant placed in the eye that releases medication slowly, so patients need treatment only every 24 weeks instead of every 4 weeks. It involves 68 Chinese adults with wet age-related macular degeneration who have already responded to standard injections. …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 08:55 UTC
-
New hope for macular degeneration patients who failed standard treatments
Disease control Recruiting nowThis early-stage study tests a new drug called PRL3-zumab in 15 people with wet age-related macular degeneration (nAMD) who did not improve with standard treatments. The drug is given through a vein every two weeks for three doses, and patients are monitored for 24 weeks. The goa…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated May 26, 2026 08:54 UTC
-
New eye implant for wet AMD tested for cell safety
Disease control Recruiting nowThis study looks at the safety of a refillable eye implant (PDS) that delivers the drug ranibizumab for wet age-related macular degeneration. Researchers will check if the implant affects the health of cells on the inside of the cornea. About 188 people with wet AMD will take par…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 26, 2026 08:53 UTC
-
One shot to tame wet AMD? new trial tests Long-Lasting eye drug
Disease control Recruiting nowThis study tests a single injection of SAR402663 into the eye for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if one dose can safely control the disease and reduce the need for frequent eye injections. About 66 adults…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
Eye implant could reduce need for frequent shots for blinding disease
Disease control Recruiting nowThis study is checking the long-term safety of a small implant placed in the eye that continuously releases medicine for wet age-related macular degeneration (nAMD), a condition that can cause rapid vision loss. About 1,000 people who have already been in earlier studies of this …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
One-Shot gene therapy could slash eye injections for wet AMD
Disease control Recruiting nowThis study tests a one-time gene therapy called surabgene lomparvovec (ABBV-RGX-314) for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 561 adults aged 50 and older who have already been treated for nAMD will receive either the gene…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New eye implant refill every 36 weeks could reduce treatment burden for wet AMD patients
Disease control Recruiting nowThis study tests whether refilling a small eye implant (port delivery system) with medication every 36 weeks is effective and safe for people with wet age-related macular degeneration. About 250 participants who have already responded to standard injections will receive the impla…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Home eye scanner could slash need for injections in wet AMD
Disease control Recruiting nowThis study tests whether people with wet age-related macular degeneration (AMD) can use a home device to scan their own eyes daily. The scans would tell doctors when treatment is needed, instead of following a fixed schedule. The goal is to maintain vision while possibly reducing…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
One-Shot gene therapy could end monthly eye injections for wet AMD
Disease control Recruiting nowThis early study tests a new gene therapy called LX111 for people with wet age-related macular degeneration (nAMD). The goal is to see if a single injection into the eye can safely control the disease and reduce the need for frequent anti-VEGF injections. Ten participants aged 50…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New eye injection could help save sight in wet AMD patients
Disease control Recruiting nowThis study tests a new medicine called IBI302, given as an eye injection, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can prevent vision from getting worse over one year. About 800 adults aged 50 and older w…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
New study observes how faricimab works in everyday eye care
Knowledge-focused Recruiting nowThis study is collecting information from 850 people with wet age-related macular degeneration or diabetic macular edema who are being treated with faricimab. Researchers want to see how well the drug works in real-world settings, how it is used, and its safety over two years. Th…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated May 20, 2026 11:57 UTC